CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery

Abstract

BackgroundMultiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). In the murine experimental autoimmune encephalomyelitis (EAE) model of MS, T regulatory (Treg) cell therapy has proved to be beneficial, but generation of stable CNS-targeting Tregs needs further development. Here, we propose gene engineering to achieve CNS-targeting Tregs from naïve CD4 cells and demonstrate their efficacy in the EAE model.MethodsCD4+ T cells were modified utilizing a lentiviral vector system to express a chimeric antigen receptor (CAR) targeting myelin oligodendrocyte glycoprotein (MOG) in trans with the murine FoxP3 gene that drives Treg differentiation. The cells were evaluated in vitro for suppressive capacity and in C57BL/6 mice to treat EAE. Cells were administered by intranasal (i.n.) cell delivery.ResultsThe engineered Tregs demonstrated suppressive capacity in vitro and could efficiently access various regions in the brain via i.n cell delivery. Clinical score 3 EAE mice were treated and the engineered Tregs suppressed ongoing encephalomyelitis as demonstrated by reduced disease symptoms as well as decreased IL-12 and IFNgamma mRNAs in brain tissue. Immunohistochemical markers for myelination (MBP) and reactive astrogliosis (GFAP) confirmed recovery in mice treated with engineered Tregs compared to controls. Symptom-free mice were rechallenged with a second EAE-inducing inoculum but remained healthy, demonstrating the sustained effect of engineered Tregs.ConclusionCNS-targeting Tregs delivered i.n. localized to the CNS and efficiently suppressed ongoing inflammation leading to diminished disease symptoms.

After Moving of Regulatory T-Cell Therapy to the Clinic: Will We Need a New Tregs Source?

“…32,33 Several animals studies support that CAR-expressing Tregs can be efficacious in preventing experimental autoimmune encephalitis (EAE) 34 or murine colitis and its associated cancer 35 or may be in the future will support the efficacy of CARexpressing Tregs in the setting of transplantation. According to in vivo expansion of nTregs, many variety of strategies used to induce Treg number or potency in vivo including expansion of nTregs and conversion of non-Tregs to iTregs like, prevention of allograft rejection in mice by treating mice prior to allografting with a donor alloantigen and a non-depleting anti-CD4 antibody which achieves Treg expansion.…”

Clinical Development and Manufacture of Chimeric Antigen Receptor T cells and the Role of Leukapheresis

“…93 In addition, CAR-transduced regulatory T cells (Tregs) are being investigated in non-oncology settings including autoimmune disorders and haemophilia 94,95 and CAR T cells that are specific to HIV infected cells.…”

Screening and identification of human ZnT8-specific single-chain variable fragment (scFv) from type 1 diabetes phage display library

“…CARs were applied in immunology and got some interesting results. Tregs expressing CARs against specific antigens have been tested and their functions have been verified in vitro and in vivo (Elinav et al, 2009;Fransson et al, 2012;MacDonald et al, 2016), which provided a basis to develop the immunotherapy for autoimmune disease by CAR-Treg.…”